34.09
-0.11 (-0.32%)
-0.11 (-0.32%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
CHART Trader
Monthly Subscription
for only
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
Small Cap Basic
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Pfizer Inc | PFE | NYSE | Common Stock |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
-0.11 | -0.32% | 34.09 | 04:26:32 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
34.20 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
30 | 1,381 | 41,850,245 | 27.88 - 42.77 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
04:24:50 | formt | 100 | $ 34.09 | USD |
Pfizer Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 189.49B | 5.56B | 5.56B | $ 51.75B | $ 13.02B | 2.88 | 23.40 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ 1.44 | 4.22% | - | - |
Pfizer News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PFE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 33.84 | 35.085 | 33.36 | 33.91 | 38,028,790 | 0.25 | 0.74% |
1 Month | 34.94 | 35.085 | 33.36 | 34.29 | 32,534,764 | -0.85 | -2.43% |
3 Months | 41.97 | 42.07 | 33.36 | 36.27 | 37,784,698 | -7.88 | -18.78% |
6 Months | 36.60 | 42.77 | 33.36 | 37.12 | 36,799,929 | -2.51 | -6.86% |
1 Year | 34.70 | 42.77 | 27.88 | 36.18 | 33,584,792 | -0.61 | -1.76% |
3 Years | 35.82 | 46.47 | 27.88 | 38.11 | 25,423,133 | -1.73 | -4.83% |
5 Years | 29.55 | 46.47 | 27.88 | 36.46 | 23,967,409 | 4.54 | 15.36% |
Pfizer Description
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor. |